Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Licensing Deals May Become More Adversarial Following MedImmune Ruling

Executive Summary

The Supreme Court's ruling that MedImmune is entitled to challenge a patent it is licensing from Genentech will likely create a more contentious environment for parties negotiating licensing deals

You may also be interested in...



Latest PTO Ruling On Cabilly May Offer Ray Of Hope To Genentech Licensees

The U.S. Patent and Trademark Office's rejection of Genentech's Cabilly patent was little surprise after the office's non-final rejection in 2005, but it may make Genentech's licensees more upbeat now that an end to royalty payments is a small step closer

Latest PTO Ruling On Cabilly May Offer Ray Of Hope To Genentech Licensees

The U.S. Patent and Trademark Office's rejection of Genentech's Cabilly patent was little surprise after the office's non-final rejection in 2005, but it may make Genentech's licensees more upbeat now that an end to royalty payments is a small step closer

Patent Reform Bill Gets Cool Reception From Rx Industry; Damage Cap Is Worry

A new patent reform bill introduced in Congress is likely to undergo revisions in the face of criticism from the pharmaceutical industry

Related Content

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel